Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBITDA Margin (2022 - 2025)

Bioregenx has reported EBITDA Margin over the past 4 years, most recently at 263.93% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 373109.0% year-over-year to 263.93%; the TTM value through Dec 2025 reached 83.34%, up 90170.0%, while the annual FY2025 figure was 83.34%, 90170.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 263.93% at Bioregenx, down from 14.44% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 161.38% in Q3 2022 and troughed at 3995.01% in Q4 2024.
  • A 4-year average of 407.2% and a median of 66.16% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: tumbled -395701bps in 2024 and later soared 373109bps in 2025.
  • Year by year, EBITDA Margin stood at 62.09% in 2022, then skyrocketed by 39bps to 38.01% in 2023, then crashed by -10411bps to 3995.01% in 2024, then surged by 93bps to 263.93% in 2025.
  • Business Quant data shows EBITDA Margin for BRGX at 263.93% in Q4 2025, 14.44% in Q3 2025, and 41.6% in Q2 2025.